The rosiglitazone story--lessons from an FDA Advisory Committee meeting

N Engl J Med. 2007 Aug 30;357(9):844-6. doi: 10.1056/NEJMp078167. Epub 2007 Aug 8.
No abstract available

MeSH terms

  • Advisory Committees
  • Diabetes Mellitus, Type 2 / drug therapy*
  • Drug Approval*
  • Drug Evaluation / standards
  • Humans
  • Hypoglycemic Agents / adverse effects*
  • Meta-Analysis as Topic
  • Myocardial Ischemia / chemically induced
  • Product Surveillance, Postmarketing
  • Rosiglitazone
  • Thiazolidinediones / adverse effects*
  • United States
  • United States Food and Drug Administration*

Substances

  • Hypoglycemic Agents
  • Thiazolidinediones
  • Rosiglitazone